- Home
- SKYE
as 03-13-2025 4:00pm EST
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 80.7M | IPO Year: | N/A |
| Target Price: | $18.67 | AVG Volume (30 days): | 136.4K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.31 - $17.65 | Next Earning Date: | 03-21-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Skye Bioscience Inc. Common Stock News
SKYE Breaking Stock News: Dive into SKYE Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
18 days ago
Skye Bioscience to Participate in SXSW Session on Obesity
Simply Wall St.
20 days ago
We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely
GlobeNewswire
22 days ago
Skye Bioscience to Present at TD Cowen Health Care Conference
GlobeNewswire
a month ago
Skye Bioscience Announces Participation in February Conferences
GlobeNewswire
2 months ago
Skye Bioscience Provides 2025 Look Ahead and Year in Review
GlobeNewswire
3 months ago
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
GlobeNewswire
4 months ago
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Compare SKYE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SKYE Skye Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.